Summary: MAPS Founder Rick Doblin, Ph.D., joins an episode of the Neurohacker Collective’s podcast, Collective Insights, and speaks with host Dr. Heather Sandison about MAPS’ multidisciplinary approach to psychedelic research, education, and drug development, from the origin of MAPS to the future of psychedelic medicine. “We want to show that once we market MDMA, assuming we get approval from FDA, that we can market a drug in a way that maximizes public benefit, not profit,” explains Doblin. “then we hope that that will become a model for psychedelic medicine as it goes forward.”
Originally appearing here.
